Related Experiment Videos
[Percutaneous treatment with BCG in multiple upper tract transitional cell carcinoma]
J Palou Redorta1, A M Autran, R H Martínez Rodríguez
1Servicio de Urología Fundacio Puigvert, Barcelona. jpalou@fundacio-puigvert.es
Actas Urologicas Espanolas
|November 25, 2005
Summary
Upper tract transitional cell carcinoma, a rare cancer, can be effectively treated with minimally invasive percutaneous surgery and Bacillus Calmette-Guérin (BCG) immunotherapy to reduce recurrence.
Area of Science:
- Urology
- Oncology
Background:
- Upper tract transitional cell carcinoma (UT-TCC) is a rare malignancy.
- UT-TCC often co-occurs with bladder cancer.
- Endoscopic antegrade access is a safe and effective minimally invasive surgical approach.
Observation:
- This case study focuses on a patient diagnosed with multiple UT-TCC.
- The patient underwent percutaneous surgery for treatment.
- Bacillus Calmette-Guérin (BCG) immunotherapy was administered post-surgery.
Findings:
- Percutaneous surgery provides an efficient and minimally invasive treatment option for UT-TCC.
- The combination of surgery and BCG immunotherapy appears to be effective in reducing tumor recurrence.
- This approach offers a viable alternative for managing complex UT-TCC cases.
Implications:
- Minimally invasive techniques like antegrade endoscopic access are crucial for UT-TCC management.
- Adjuvant immunotherapy, such as BCG, may play a significant role in preventing recurrence after surgical treatment.
- Further research into combined treatment modalities could optimize outcomes for patients with UT-TCC.